Genistein

Genistein

$30.40
COR10

Genistein is a practitioner-only listed medicine containing Glycine max seed extract, standardised to provide genistein 48 mg per capsule. It is intended for qualified healthcare practitioners seeking support for bone mass, bone density and menopausal symptoms in post-menopausal women.

30 capsules | AUST L 199015

Each capsule contains:

Glycine max seed dry extract 100 mg
Equivalent to Glycine max dry seed 600 mg
Containing genistein 48 mg

Extract ratio: 6:1
Extraction solvent: ethanol absolute 80%, purified water 20%

Genistein is formulated to:

  • maintain / support bone mass in post-menopausal women
  • maintain / support bone density in post-menopausal women
  • maintain / support bone integrity in post-menopausal women
  • help reduce occurrence of menopausal symptoms

Directions

Take 2 capsules twice daily, or as directed by a qualified healthcare practitioner.

After initial practitioner-directed use, dosage may be adjusted based on individual assessment.

Label statement

If symptoms persist, talk to your health professional.

This section is provided for qualified healthcare practitioners as professional education. It summarises selected ingredient-level and pathway-level research relating to Glycine max, genistein, soy isoflavones, post-menopausal bone health and menopausal symptom support. It does not represent additional ARTG indications for Genistein.

Genistein is relevant to practitioners interested in soy isoflavone research, phytoestrogen pathways, post-menopausal bone health, menopausal transition research and women’s health nutrition.

Genistein is a soy isoflavone found in Glycine max. Isoflavones have been discussed in professional literature in relation to oestrogen receptor signalling, bone turnover, menopausal symptoms and post-menopausal women’s health research.

Human clinical research has examined soy isoflavones in post-menopausal women, including bone mineral density and menopausal symptom outcomes. Some studies have reported mixed findings, which is why this information is best presented as practitioner education around ingredient-level research rather than as a disease-treatment claim.

Genistein and related soy isoflavones have also been studied in broader cellular, preclinical and epidemiological research settings, including oncology-related pathway research. Recent review literature has discussed genistein and derivatives in relation to breast cancer research mechanisms, including signalling pathways, apoptosis, angiogenesis and epigenetic pathways. This information is provided as scientific background only and does not represent an oncology indication for Genistein.

Soy isoflavone research has also been reviewed in prostate cancer-related cellular and mechanistic contexts. These studies are relevant to practitioner education around genistein’s broader research profile, but they should not be presented as clinical use directions for the finished product.

The Genistein formula provides a standardised Glycine max extract containing genistein, supporting practitioner education around post-menopausal bone health, menopausal symptom support and soy isoflavone pathways.

This information is provided for practitioner education only and does not represent additional ARTG indications for Genistein.

References available to registered practitioners on request.